iRhythm Technologies, Inc.

Hello and welcome to the iRhythm Technologies Inc Q1 2023 Earnings Conference Call. My name is Lauren and I'll be coordinating your call today. If you would like to ask a question during the presentation, you may do so by pressing star followed by one on your telephone keypad. I will now have you over to host Stephanie Sadkovich, Director of Investor Relations to begin. Stephanie, please go ahead.

Thank you all for participating in today's call. Earlier today, iRhythm released financial results for the first quarter ended March 31, 2023. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that are not statements of historical fact should be deemed to be forward-looking statements. These are based upon our current estimates and various assumptions and reflect management's intentions, beliefs, and expectations. about future events, strategies, competition, products, operating plans, and performance. These statements involve risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the risk factor section of our most recent annual and quarterly reports on Form 10-K and Form 10-Q, respectively, filed with the Securities and Exchange Commission. Also during the call, we will discuss certain financial measures that have not been prepared in accordance with US GAAP with respect to our non-GAAP and cash-based results, including adjusted EBITDA, adjusted operating expenses, and adjusted net loss. Unless otherwise noted, all references to financial metrics are presented on a non-GAAP basis. The presentation of this additional information should not be considered in isolation of, as a substitute for, or superior to results prepared in accordance with GAAP. Please refer to the tables in our earnings release and 10-Q for reconciliation of these measures, the most directly comparable GAAP financial measures. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, May 4th, 2023. iRhythm disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. And with that, I'll turn the call over to Quinton Blackford, iRhythm's President and CEO.

Thank you, Stephanie. Good afternoon and thank you all for joining us. Bryce Bobdeen, our Chief Financial Officer, and Dan Wilson, our EVP of Corporate Development and Investor Relations, join me on today's call. My prepared remarks today cover progress we've made during the first quarter of 2023 and discuss the growth initiatives for our business. I'll then turn the call over to Bryce to provide a detailed review of our financial results and updated guidance. In the first quarter of 2023, we continue to build upon the solid momentum we had exiting last year, recognizing revenue of $111.4 million, or 21% growth year over year. Our commercial team did a terrific job building upon the discipline and rigor introduced in the back half of last year to capture key strategic wins, driven by a continued push into primary care, as well as increasing penetration into large and national accounts. The outperformance in the quarter was driven by the strength of our ZOXC business, fueled by better than expected volume and another record quarter of new account openings. Additionally, we were pleased with the performance of a return device rate for the quarter, as well as the performance of our ZOAT business, which grew 21% year over year on a revenue basis, both in line with our expectations. Encouragingly, growth during the first quarter came from across the business as we saw strong contributions from all regions, deeper penetration in our existing accounts, and a record number of both new accounts and new prescribers. Volume from cardiologist prescribers grew nicely during the quarter, while contributions from primary care continued to outpace overall company growth. The interest in veal from primary care physicians continues to grow, evidenced by the significant and growing interest from large national primary care networks. We continue to believe that the primary care channel will be a nice lever for growth as we are in the very early stages of a significant market expansion opportunity. And lastly, we saw continued growth from our large blue chip accounts as our differentiated commercial strategies to drive further penetration into these valuable partners continues to deliver. Our ability to deliver value across the continuum of care by quickly and accurately detecting arrhythmias for benefit of patients by enabling better clinical outcomes and even more important in today's environment by improving healthcare resource utilization has resonated with our various stakeholders as we aim to deliver on our mission. Supporting this continued growth is a steady drumbeat of positive clinical data that continues to demonstrate Zio's value proposition and competitive differentiation in the marketplace. The Camelot data released at ACC in March was truly game-changing for patients, customers, and ZioXT in particular. This was the largest and most contemporary world-world comparative effectiveness analysis of ambulatory cardiac monitoring, retrospectively analyzing the ACM experience of nearly 290,000 diagnostic-naive patients. Compared to all other ambulatory cardiac monitors, Camelot demonstrated that long-term continuous monitoring with ZOXT was associated with the highest diagnostic yield and the fastest time to clinical diagnosis, the lowest likelihood of retesting, and the lowest acute care healthcare resource utilization. With the data now in the hands of our commercial teams and the payer relations team, we are excited to further demonstrate how consequential it can be to choose the right monitoring service the first time. As one example of the impact we are starting to see from Camelot, the Value-Based Care Council, or VBCC, of the National Association of Managed Care Physicians, or NAMCP, has validated through an independent third-party review of evidence that ZOXD contributes value to health systems and payers. The NAMCP offers educational materials, evidence-based tools and resources to help medical directors from purchasers, plans and provider systems to make effective and informed decisions. The Value-Based Care Council is composed of medical directors and chief medical officers from around the country who have experience and knowledge about value-based care, along with corporate members from the industry who share these interests. In their final report, after an objective review of ZOXT claims and evidence, they showed that the value proposition for ZOXT is credible and objective related to diagnostic yield, analyzable wear time, detection of many types of arrhythmias, lower likelihood of retesting compared with other monitoring types, improved clinical out times, and decreased time to diagnosis. Additional details and full results of this important collaboration will be announced at a later date. We believe Camelot data demonstrates that ZOHD should be the gold standard for long-term continuous monitoring. But we also believe that the commercial release of our ZO monitor represents an improvement to the already high bar we've set for ourselves. In addition to its inconspicuous profile, the pliability of the new Xeo Monitor allows for comfortable wear and is designed to improve patient compliance and satisfaction. Initial real-world and clinical experience data with Xeo Monitor, also presented at ACC, demonstrated high patient compliance with the potential to extend wear times in the future. Fourteen-day data from 673 patients wearing Xeo Monitors demonstrated higher compliance, and higher-quality ECG compared to ZOXT, while 30-day extended-wear monitoring yielded additional clinical findings beyond 14 days. Post-clearance evaluations of ZO Monitor showed consistent and even improved performance compared to ZOXT, with potential to greatly improving monitoring and decision-making for more complex patients. We continue to expect the full launch of ZO Monitor later this year, with the new platform providing significant product optionality into the future. As we continue to drive towards realization of opportunities for future growth, we are just as committed to driving growth in a scalable, sustainable manner. As mentioned on our last earnings call, we established a global business services center, and we are working toward ongoing business transformation activities to position the company to maintain patient satisfaction, scale globally, and perform more efficiently. We have hired a dedicated GBS leader along with a team that is now in place and anticipate opening our Manila office during the second quarter. During the first quarter, we also announced internal restructuring to better align the organization to pursue our strategic objectives and to drive operational efficiency, alignment, and focus. This allows us to increase the pace of organizational execution by realigning many functions in the business to create synergy, enabling our groups to work more efficiently, and to scale more quickly. We look forward to how this will continue to elevate our ability to serve millions more patients as we continue our rapid growth. Furthermore, our commitment to operating as responsible corporate stewards was highlighted in a recently refreshed ESG report released in April. This report and the excellent work by so many around the company that it represents reflects the elevated focus our organization has on ESG matters and reconfirms our commitment to growing responsibly and sustainably for the benefit of patients, customers, communities, employees, and the environment. Our company profile and the nature of our products dovetails nicely with ESG initiatives, be it the reusable, recyclable profile of our Xeo device, our continued emphasis on equitable access to care, or our unwavering commitment to patients in the communities which we serve. But this report is also a nice example of the governance mechanisms we've put in place over the past year to embed ESG policies and initiatives into our operations as we continue to transform the company. We look forward to communicating progress against our roadmap in the future as a continued driver of long-term value creation for our stakeholders. Before turning to Bryce, there's one final item on which I'd like to comment. As we will disclose in our 10-Q file today, after the quarter closed on April 4th, we received an inquiry from the Civil Division of the U.S. Department of Justice seeking information and documents regarding the company's products and services. Our teams are working on responding to the DOJ's inquiry and we will fully cooperate with the department's request. At this point, we are very early in this process of engaging with them and it's too early to speculate on the precise motivations behind their inquiry or any anticipated duration of the engagement. As we have more information, we will be sure to provide the necessary updates. In closing, we remain bullish on the business for 2023 and beyond. Continuing on the solid momentum of late 2022, we have begun the new year in a very strong position to drive continued growth in our core business and making the investments necessary to transform the company. We believe that we are well positioned to capture the opportunities ahead while efficiently scaling our operations and have never been more excited by the future that we see in front of us. With that, I will now turn the call over to Bryce to discuss our financial performance.

Thanks, Quentin. As a reminder, unless otherwise noted, the financial metrics that I discussed today will be presented on a non-GAAP basis. Reconciliations to GAAP can be found in today's earnings release and on our IR website. As Quentin mentioned, first quarter results demonstrated continued momentum as we realized revenue of $111.4 million, representing 21% year-over-year growth. This strength was driven by significant volume growth in our core U.S. business, slightly offset by a low single-digit pricing decline in line with expectations. With national CMS rates in place as of January 1, 2023, we began leveraging our San Francisco IDPS with approximately 25% of DOXT volume processed through the San Francisco location, also consistent with expectations. Looking at new store, same store mix, new store, defined as accounts that have been open for less than 12 months, accounted for almost 35% of our year-over-year growth. While we continue to drive record new account openings, contributing significant growth, this new store, same store contribution mix is also reflective of tremendous volume growth from existing accounts, implying reduced account turn and increasing penetration in these accounts. Home enrollment for Xeo Services was about 20% of volume in the first quarter. Moving down the rest of the P&L, gross margin for the first quarter was 67.9%, representing a 200 basis point decline compared to fourth quarter 2022. This decline was primarily driven by expected ASP fluctuations sequentially as we began processing claims for the CMS business at updated national rates beginning January 1st, as well as expected slight declines in our commercial realized ASPs. However, gross margin in the first quarter 2023 represented 100 basis point improvement from first quarter 2022. This was driven by a reduction in unit cost to serve as we ramped volume significantly and were able to leverage our fixed cost infrastructure, offset by year-over-year pricing headwinds. Note that cost of revenue during the first quarter 2023 included some duplicative costs as we began to leverage third-party providers for certain clinical operations and customer care services to enable growth and scale our operations. First quarter adjusted operating expenses were 109.5 million, up 13% sequentially and 31% year-over-year. The spend in the first quarter was generally in line with expectations, with the increase primarily driven by increased personnel expenses to support volume growth and elevated commissions for volume outperformance in our core business. There were also some duplicative costs incurred in our operating expenses during the first quarter as we stand up our global business services center in the Philippines. Importantly, We also made incremental investments in R&D as we finalized development of our ZIO monitor to prepare for commercial launch later this year, continued developing our ZIO MCT product that we plan to submit for regulatory approval in the third quarter, and advanced initiatives in adjacent market opportunities. Adjusted net loss for the first quarter was $33.4 million, or a loss of $1.10 per share, compared to adjusted net loss of $17.9 million, or a loss of $0.59 per share in the fourth quarter of 2022. This compares to adjusted net loss of 80 cents per share or a 30-cent decline versus first quarter 2022. We reported approximately 5.7 million of expenses related to business transformation activities in the first quarter 2023, but also recall that in the first quarter of 2022, we incurred 26.9 million in impairment, restructuring, and transformation charges primarily associated with the reduction in size of our San Francisco facility. Adjusted EBITDA in the first quarter of 2023 was negative $12 million, reflecting a decline of $13.1 million sequentially and a decline of $7.2 million year-over-year. While this represented reductions compared to the fourth quarter of 2022 and the first quarter of 2022, this short-term decrease in adjusted EBITDA margin resulted from investments being made to our near-term volume growth drivers as well as long-term initiatives. Turning to guidance. We're updating our outlook to reflect anticipated four-year revenue growth of approximately 17 to 19% compared to 2022, representing a range of approximately 480 to 490 million, contemplating our outperformance in the first quarter of 2023. Our outlook on anticipated pricing remains unchanged compared to prior expectations. We expect seasonality in line with non-pandemic historic trends with approximately 25% of full year revenue anticipated in the second quarter of 2023. We continue to believe that gross margin will range between approximately 69 and 70% for the full year. Incremental gross margin improvements will be realized through volume growth contributions to our per unit cost, as well as improvements to our fixed cost structure. Recall that our full year guidance contemplates a bit of pressure to gross margins in the as we ramp to launch our Xeo Monitor service into the U.S. commercial marketplace. This will include an evaluation of our current XT inventory levels and may reflect underutilized costs for our Xeo Monitor system as we scale the new product. We now anticipate that adjusted operating expenses in 2023 will range between approximately $417 and $427 million, including updated variable compensation reflected as a result of increased volume demand. This quarter included some seasonal items that will not repeat for the remainder of the year, such as the return of our in-person global sales and leadership meetings for the first time in the last several years. Additionally, as we stand up our global business services center in the Philippines and begin to leverage third parties, duplicative costs incurred in the first quarter will begin to step down over the remainder of the year. As a result, we anticipate that overall operating expense levels on a quarterly basis will step down slightly compared to the first quarter for the remainder of the year. Thus, we continue to believe that adjusted EBITDA margin in 2023 will range between approximately minus 0.5 and 0.5% of revenue. As a reminder, adjusted EBITDA will continue to exclude restructuring costs, transformation costs, and stock-based compensation expense. In 2023, we continue to anticipate incurring approximately 15 to 20 million of one-time non-GAAP business transformation and restructuring costs related to the ongoing globalization efforts to drive efficiency, improve scalability, and provide continued high-quality customer and patient experience. We believe that the expenses incurred related to these activities in 2023 will further enable operating leverage into the future, especially as we grow to serve more patients in our core markets and internationally. Note that adjusted operating expense and adjusted EBITDA guidance do not include costs related to the Department of Justice inquiry, as we are very early in the process of engaging with the department. Finally, we ended the first quarter in a strong financial position with $176.3 million of cash on hand to drive continued growth in our core business, invest in innovation, and lay the foundation for future expansion. While we continuously review our capital structure to support the best interests of the company and our stakeholders, we are confident in our liquidity position to operate our business for the foreseeable future. We could not be more excited for the strong momentum in the business to continue and look forward to upcoming catalysts that we anticipate can drive growth in 2023 and beyond. With that, Quintin, Dan, and I would like to now open the call for questions. Operator?

Thank you. If you would like to ask a question, please press star followed by one on your telephone keypad. If you changed your mind, please press star followed by two. When preparing to ask your question, please ensure that your phone is unmuted locally. We also ask that you limit yourself to one question and one follow-up question. Our first question comes from Alan Gong from J.P. Morgan. Alan, please go ahead.

Hi, thanks. Congrats on the good quarter. I just had one quick one on the quarter and then a follow-up, but definitely encouraging to see the quarter starting off on a bit of a strong note with AT growing 21%. But when I think about, you know, you had talked about how it seems like AT is improving, device return rates are improving. How is that really tracking relative to expectations so far in the second quarter? And what more do you need to see, you know, before we can maybe see guidance moving up, you know, not to beat a dead horse, but up towards like, you know, that 20% LRP?

Yeah. Hey, Alan. Thanks for the question. I've been very pleased with what I've seen in the business thus far with return device rates in the AT business. I would say that more or less we've been right in line with our expectations, if not slightly ahead of where we expect it to be, but not materially. You look at the first quarter, the driver of the business is just the underlying volume strength that we're seeing. Our registrations in the quarter were up in the mid to high 20s. you know, as we start to approach 30%, some of the strongest registration growth we've seen in almost two years now. And that's getting back into some COVID comparisons that start to get a little bit unique, right? So the registration growth has been phenomenal. And that's really what's driving the overall growth in the business. I still continue to believe that, you know, as we make progress with return device rates and AT returns to historic growth rates, that has the opportunity to provide some upside to the guidance that we've laid out

um today but but really the strength of the quarter was driven on the registration growth in the business got it and then you know for a less fun question you know this uh department of justice inquiry is news to us you know i i believe you said it was civil so hopefully downside is kind of limited but you know when i think about you know do you have any sense of what they're actually looking into the kind of timelines that you should expect for any updates on the process and just kind of what the downside could be to the inquiry. Thank you.

Yeah, I think it's a bit early at this point, Alan, to really articulate anything more clear around the matter itself. We certainly will engage with the DOJ and try to learn as much as we can, and we'll communicate as we have more clarity around what that looks like. I think at the end of the day, we know that within this industry, these things occur from time to time. We understand that. I will tell you, we've done an incredible amount of work over the course of the last 12 to 18 months, you know, with the new leadership team in place, building out incremental more robust capabilities. We've put in place a chief risk function, a chief risk officer. We have a dedicated compliance function. I mean, we've continued to mature the organization, you know, over the last year or so that That continues to give me confidence that quality, compliance, all of these things are very important to us and will continue to be, and we're elevating our capabilities in the organization. But to give you any specifics on what they might be focused on or where their focus is at, it's just too early at this point, and there's not a whole lot more we can comment on at this point in time. But as we do get more information, we'll certainly be sharing it.

Thank you. Our next question comes from Margaret Caxall from William Blair. Margaret, please go ahead.

Hi, everyone. This is Macaulay on for Margaret. Thanks for taking our question and congrats on the quarter. So obviously the PCP momentum has continued. And from our channel checks, what we've heard is there's been better access to iRhythm compared to before. Are there certain partnerships where that is happening more than others? And then just as a follow-up, is there a certain type of patient you're seeing now more than previous before you kind of had these partnerships?

Yeah, no, thanks for the question. I'll tell you on the access side, we spent a lot of time over the course of 2022 really working to ensure that patients that needed access to our product could get it. And nearly 93% of all patients from a commercial perspective, have access into our product, the vast majority of which without any prior authorization for ZOXD. So I think we've done a terrific job increasing access, creating awareness around it. One of the things that we're seeing in the marketplace, and the product is so easy to use and apply that in many times, cardiologists are actually recommending that the primary care physicians, particularly within their own network, begin to prescribe the product and have the product applied much further upstream because it helps them really identify which patients they then need to see further downstream and spend time with. And so I think you've got the cardiologists who are making the push for this device to be utilized in more of the primary care setting. We're going directly at the primary care network. We announced the agreement last quarter with One Medical. We continue to expand those with additional primary care networks that only increase the utilization of the product in that primary care space, and certainly elevate the awareness of the value of the product. So I think it's a combination of things, both access that we're working to create and doing a nice job improving, but also just creating a lot of awareness in the primary care channel with respect to how easy this product is to use and how it can help them streamline the patients they're caring for and where they need to go next within their networks.

That's great. And then just one real quick on Xeo Monitor in terms of what's being assumed in the mix between Monitor and Xeo XT once it does enter the full launch.

Yeah, it's a good question. Thanks for asking. I would say, you know, from a guidance perspective, we're not necessarily anticipating an acceleration in volume or anything specifically related to Xeo Monitor. What I would say is we absolutely believe this is a great product, and there's absolute opportunity for upside with it. But from a guidance perspective, not necessarily anything baked in specific to Monitor.

Great. Thanks again for taking the questions. Thank you.

Thank you. Our next question comes from . Marie, please go ahead.

Hi, congrats on a great quarter, and thanks for taking the questions. I wanted to ask my first here on the Novitas final LCD that was out. We certainly get some questions on it, and just wanted to hear your latest thoughts on the risk around that LCD, the possibility of spread to, you know, a Noridian or a different geography, and any details you can offer on, you know, the number of prescriptions, you know, that would meet the EKG requirement. Any details around that?

Hey, Marie. Thanks for the question. Now, look, I don't view the final LCD out of Novitas as anything that gives me any concern, really, at all. I don't think it's significantly restrictive. I think it mirrors, quite frankly, many of the commercial policies that are already out there that we navigate in and around every single day. I mean, at the end of the day, you look at where they landed with the final position of their LCD, and the reality is there's a handful. You can probably count 10 to 12 different sort of criteria that, so long as the patient is meeting or the physician believes it is taking place, enables or allows them to prescribe a patch technology. And I think the initial concern was, is there going to be a requirement for a 12-lead ECG to be performed before they can step into something else? That's not the case at all. That's one of the 12 criteria, but they're all sort of ors, if you will. meaning if you meet any one of those significant list of criteria. So I don't view this as anything that's going to impact sort of the momentum in the marketplace. Again, it's very much in line with what we see with the majority of our commercial payers. And if you get into the details, even on the 12 lead ECG, for example, you just start to do some market checks, you're going to find that north of 80%, upwards of even 90% of physicians are already capturing this sort of information. And And we're providing it, like I said, in the commercial payer universe already. So I don't have any concerns around it. Certainly we're mindful of it, but it's a normal part of how we operate the business today and how the physicians, I believe, interact with their patients today. So no real concern from our perspective there.

Okay, good to hear. Good to hear you confirm that. I'll ask my follow-up here on the San Francisco facility. It sounds like about 25% of the volume is being processed through that facility. What are you expecting in the numbers you've given us for Q2 on guidance in terms of the shift toward that? How is hiring and sort of all the hurdles you need to jump to shift more volume going on that side? And thanks for taking the questions.

Sure.

Hey, Mary.

It's Bryce. So, yeah, we still anticipate about 50% of the full-year volume running through the San Francisco IDPF, no differential from what we anticipated from the beginning of the year. And as you can imagine, that would imply a ramp throughout the year. As it stands now, hiring is going well. It's still something we monitor on a regular basis, but no deviation from the contemplation in the original guidance.

Very good. Thank you.

Thank you. Our next question comes from Nathan Trebek from Wells Fargo. Nathan, please go ahead.

Hi. Thanks for taking the questions. Can you talk about the ASP declines you saw as you began processing the new national rate? And how should we think about this as you shift your volumes to the San Francisco IDTF? Thanks. Sure.

Hey, Nathan.

This is Bryce.

Yeah. So, in the first quarter, if you remember looking back into 2022, From a CMS perspective, we were still navigating most of the volumes through the Houston IDTF. At that point, it was at a lower ASP point than what we ultimately ended up pushing through Chicago. So in the specific to XT, I would say there's actually a bit of pricing tailwind from a CMS perspective on the XT side. Now, I will say on the AT side, it's almost exactly the other way, and they effectively net each other off. There's a bit of overall pricing pressure. But on the AP side, the national rate was established and call it 11% less than what we saw in 2022. All volumes on the AP side go through San Francisco, both in 2022 as well as 2023. So that 11% impact is basically the way you can think about AP. On the commercial side, that low single digits played through. A portion of that was those commercial contracts that are tied to the CMS rate. The other portion of that would just be normal course of business and contracting. So effectively, it came in right in line with expectations as we think about Q1. And again, that's the reason we reiterated the ASP guide for 2023. Great. Thanks.

And in terms of the CEO monitor, Over what timeframe should we think about you kind of moving all your volumes, your XT volumes to the monitor? And as that happens, how should we think about margins? Thanks.

Yeah, I think from a commercial perspective, you're going to see that migration taking place over the course of 2024. Obviously, I think As quickly as we can move towards the monitor, we're going to want to do that. But at the same time, you know, we're ramping production volumes. We're introducing some automation on the VO monitor so that we can produce that at a lower cost in time and at scale. And so all of those are going to play into sort of how quickly we can work through that conversion. But the hope is to get the monitor as quickly as we possibly can. I think in terms of the gross margin progression, you know, Bryce, certainly feel free to speak to that. We know that we're going to have a bit of pressure in the third quarter, late third quarter, sort of as we think about transitioning into the release of Monitor. And it's not at full scale, so it's going to put a bit of pressure on the gross margin. We also got to think about how we step out of the DOXT product, and do we have any inventory charges that we have to look at from a reserves, excess, obsolescence. And so we'll pay attention to those sort of things, all of which is contemplated in our forward-looking guidance. But then once we get into monitoring, start to really build that and ramp it and work into the efficiencies of that automation, I think you're going to see some benefits in that gross margin line. So we'll give more color and clarity around that when we're ready to set expectations for 24, but we certainly see ZIO Monitor as something that can drive some nice gross margin improvement for us into the future.

Great. Thanks.

Thank you. Our next question comes from Cecilia Furlong from Morgan Stanley. Cecilia, please go ahead.

Great. Good afternoon, and thank you for taking the questions. I wanted to ask about AT. Just following some of the recent disruption, it did look like strength in the quarter, but as you think going forward, are you back to what feels like a normalized growth rate for AT? How are you factoring that into your guidance relative growth versus XT? I wanted to ask, too, just tied in with that, for you, MCT, coming out in the future, how you're thinking about timeframe for that, if it's 30 days, shorter, just above your outlook at this point.

Sure. So, I think from an AT perspective, Cecilia, Bryce sort of mentioned this in some of his comments earlier in response to one of the questions. You know, we saw, I would say, low teams in terms of pricing pressure coming out of the AT business. TAB, Mark McIntyre:" rate that was down about 11% with respect to at and on the commercial side, a couple points of incremental pressure there so think about it as the low. TAB, Mark McIntyre:" You know teams in terms of pricing pressure and we communicated that the at business grew around 21% so from a volume perspective at was up in the mid 30s. TAB, Mark McIntyre:" that's down from where it was that you know, last year, which was closer to the the upper 40 so we're not back to those historic growth rates. But yet it is growing in line with sort of how we expected it would in the guidance that we set. So to the degree that we can get that back up into those historic growth rates, then there's upside to the financial forecast that we put out there. But that's not something that we necessarily want to get ahead of ourselves with. We want to see that show up in the results and then we can reflect it more aggressively in the financial guidance that we put out there. But I will say we've been pleased with the progress. With respect to ZOMCT, You know, we hope to get on file with the FDA here in the mid part of the year. Everything's tracking very well to that, really pleased with the progress the teams have made to get on file from an FDA perspective. And then we would look to have approval sometime out in 24 and then potentially have that product into the market in the back part of 24. The idea would be certainly to have an extended wear period beyond the 14 days that our DOAT has today. Not sure we get all the way to the 30 days, but we're going to be a whole lot closer to it. And I think start to really eliminate this argument from a competitive perspective that, you know, 14 days may not be enough for what they're looking for. And while we don't get all the way to 30 days, it's close enough in that it starts to eliminate that issue for us altogether. So I'm excited by what we're going to see with UMCT. I think it's a terrific product. I would say we're not waiting for MCT to continue to work on closing the gaps in our AT portfolio, we'll introduce the AF burden onto our ZOAT product here in the next 30 to 45 days or so into the US marketplace, which continues to enhance the value proposition of that particular product for us. So there are reasons we can get back to those historic growth rates this year, but we want to see that play out before we start to really reflect it in our guidance more aggressively.

Great. I appreciate the call. And then just turning again to PCPs and the strength that you've seen there, I don't know if there are any metrics you can put around it, but just how you're looking at 23 contributions going through that channel versus what we saw in 22. And from a top line standpoint, really how you're thinking about that reflected in your overall guidance range. And thank you for taking the questions.

Yeah, I will tell you, I think a lot of the volume strength that we saw in the first quarter, again, a record for us in nearly two years now, is being fueled by the strength of the primary care adoption of the technology. Now, it's interesting in terms of how it's showing up. And I think you see a little bit of this in the statistic that Bryce pointed out in terms of 35% of our growth is coming from new accounts and call it 65% coming from existing accounts. But what you're seeing is in those existing accounts, a lot of further penetration into the account itself and starting to work with the primary care physician within the account versus just the cardiologist. It's driving a lot of the growth in our existing accounts as well as we move into other channels of the account we're already in. I think it's a bit too early to give specific measures around the progress with respect to PCP. I think that's something we'll continue to think about into the future. But right now, I would tell you the majority of the outperformance is really coming from these incremental channels that we're starting to really position the product for, but also utilizing the voice of the cardiologist just in terms of how easy the product is to move it further upstream and and get into these other channels. And it's quite encouraging in what we're seeing. As I shared, you know, the strength of the quarter was on the back of the true underlying volume in the period itself. We want to see that continue to play out before we update any financial guidance, but very encouraged by what we're seeing there.

Great. Thank you.

Thank you. Our next question comes from Richard Neuwitter from Truist. Richard, please go ahead.

Hi. Thanks for taking the questions. Quentin, I was hoping or wondering, could you comment a little bit on the month-to-month trends through the quarter, particularly as you exited in March, and kind of what you saw in April?

It's a good question, Rich. I will tell you in the first quarter, January, February were incredibly strong months for us. We did see March pull back a bit. And we saw that remain sort of at that lower level through the early part of April, but it came back very strong in the back part of April and has been very strong here in the very early part of May as well. And I attribute that, and this is something we pay very close attention to and I think have a good finger on the pulse. I do think sort of the holiday period, the spring break period through, That late March, early April timeframe did feel like it was a bit heavier than what we've seen historically. And I think there's some other channel checks that's been validated. But what we've seen in late April and into the early part of May has been really, really encouraging and something that we're very excited to be seeing. And I think it comes back to why we just don't want to get ahead of ourselves at this point in time. But the most recent trends in the business are something we're very pleased with.

Okay, that's really helpful color. And then maybe just to follow up here, you know, thinking about the guidance move 16 to 18 to 17 to 19% now year over year, you just did 21%. I guess, A, any color you can give on the quarterly cadence between QQ and 4Q, anything you'd want to call out here? Do you feel comfortable more or less where consensus is for QQ? And then B, You know, Quinn, why wouldn't you hit the 20% marker, you know, or stay in the 20% arena for longer? I guess what's the reason why growth would decelerate things?

Yeah, Rich, I think it's a fair question. And I think there's certainly the potential there to be at 20%. But, you know, I kind of look at it as we're a quarter into the year. We certainly aren't going to get out ahead of ourselves. We're incredibly bullish on what we're seeing in the business. But I think there's a lot of economic uncertainty that continues to remain out there. And we want to be mindful of that. You know, when we put something out there and tell you that we're going to deliver on it, we want to deliver on it. And so I think we just need a little bit more time to get comfortable to raise it, you know, up into that 20% range. But certainly, you know, you look at the first quarter, return device rates were not all the way back to where they were in the prior year. AT is not all the way back to where it was. yet volume was incredibly strong. We grew north of 20%, nearly 21%. So we know that we can grow more than 20%, but we want to see this continue to play out for a little bit of time before we get ahead of ourselves. In terms of the quarterly cadence, I look at Q2. I'll give you a bit of color around it. Historically, we're going to drop 24.5% to 25% of revenue into the second quarter. I think that's the right way to continue to think about it. Sequentially, it's probably going to step up right around that 8% range or so. It's kind of how we We've modeled it, and I think that's the way you ought to think about it for the time being. And if you're around those ranges, then I think we're all probably thinking about the second quarter in a similar way. And then, look, we'll see how volumes play out, and we'll deal with the back half of the year as we have more confidence in what the volumes might look like. But right now we feel very good with that back-end guidance that we put out there.

Thank you, and congrats on the quarter.

Thanks, Richard.

Thank you. Our next question comes from Bill Plover, Nick from Canaccord. Bill, please go ahead.

Great, thanks. Good evening, and thanks for taking my questions. Something a little different. I'm just curious, you know, Medicaid, you know, is a state-by-state, and that's something I think, you know, before the Cat 1 Code, you didn't get paid on a lot, and there are a lot of states you didn't even go after. I'm just curious, If you could help us understand kind of what have you seen since the implementation of the cat one code and then, how should we think about the potential opportunity that you could pick up from this over the next in the timeframe in which you could capture this.

hey bill it's right good question medicaid is one that we're actually you know really coming onto our radar and frankly we've internally set up. a committee that's focused on just this. And so we're really taking a state-by-state approach in certain situations where we see the highest portion of our patient population ultimately coming through those channels. And so that's honestly what you have to do. You have to have a code in place, not only with the CAT code for broader coverage from basically the category being in place on the Medicare side, but also have that code in place with the individual states from a Medicaid perspective. And honestly, we're going down the line and saying, which ones do we work on first? Some are a little bit easier to get after than others, but we have a process where we're working into each. Now, I will tell you, for the most part, we're still covering those patient populations. And what's happening is effectively, you know, it's going without payment. So what you'll see as we make progress is that non-contracted bucket that we report in our 10Q will continue to shrink and ultimately it will shift up And you'll start to see the ASP benefits associated with it. So I think, you know, for us, I would say it's absolutely something we're thinking about, and we're making it a priority, and we're pushing it forward.

And, you know, if you had to quantify that, like, you know, how much of an opportunity is that, is dollar-wise? If today, if all of that Medicaid that you're not getting paid for, you know, you did get paid for it, some reasonable reimbursement rate.

Yeah. So maybe I best quantified on a unit basis where I would say, you know, effectively now maybe we're getting $25 to $30 per unit. I could see a path. It's usually a percentage of the Medicare established rate. Call it 70% depending on the state. So think about that as going from, you know, that $30 price point up to $170. haven't necessarily put volume out there as to what the percentages of that non-contract is but it's pretty substantial on a per unit basis and again not all states will happen at once but it becomes a reasonable opportunity for us okay and if i could just ask on international just any update on japan uh designation reimbursement yeah thanks bill you know certainly excited by

Justin Fields, M.D.: : By Japan, I think we're going to hear very shortly sort of the high medical needs designation whether we're going to receive that or not. Justin Fields, M.D.: : I expected sometime within the next 30 days, once we have that our file is ready to be submitted from a regulatory perspective and will be on file immediately, so I think we'll we'll be filing. Justin Fields, M.D.: : anytime here in the next you know call it 3060 days there in Japan and hope to have an approval. James Meeker- sometime in the course of 24 and then moving on to getting it into the product or sorry getting the product in the market, but we're very close, I think that. James Meeker- it's probably quite honestly been a month or two beyond where we were hoping to be, but I medical needs is something that's worth pursuing and we're going to get an answer to it soon.

James Meeker- Thank you, thanks for taking my questions.

Thank you. Our final question comes from Sergio Callia from Oppenheimer. Sergio, please go ahead.

Quentin, can you hear me all right? We got you. Sorry, I'm in a train, so pardon the background noise. So, Quentin, I'll ask two questions, both of them together. The Xeo Monitor, you know, and its introduction for, let's say, the Xeo XT 30 days, Should we think about a staged approach, first 21 days and then 30 days? And what's the status of the gateway for 21-day battery? And my second question, Quentin, where are you on the discussions with the payers for offshoring, you know, the report readout and analysis? You'll set up a facility in Manila. Curious how payers are responding to that. Thank you for taking my question.

Sure. Thanks, Raj. Appreciate the question. But, you know, XeoMonitor, just to be clear, the initial launch of XeoMonitor will replace XeoXT, which is a 14-day product. And the initial XeoMonitor will be put into the market as a 14-day product. But that platform, the very same form factor, is what will be used for our XeoMCT product when we launch that. And, you know, that's going to be anywhere from 21 to 30 days in terms of its wear period. We continue to work through that with respect to ZOMCT, but that'll be the longer duration wear period. Now, I think what you're referring to is we had put out a study, there was some trial data that was published back at ACC that just demonstrated the ZOMonitor, which again is the same form factor as what ZOMCT will be, has very successful wear properties with it all the way out to 30 days. We'll keep Xeo Monitor in terms of what's going to replace Xeo XT at the 14-day period for the time being, but I think it creates some flexibility if we wanted to think about that over a longer duration. With respect to the gateway, the gateway is something that we're working with also to extend sort of the duration of its usability, if you will. Today, you know, it's 14 days with Xeo AT, but with Xeo MCT, know i think we can get that out to 21 plus days i think you know if we start to look at that in a little bit of a different way to maybe where we make it rechargeable then of course it can go as long as it needs to go depending on how many days we we have the zio mct patch working which you know could be up to 30 days potentially so it gives us a lot of flexibility from that perspective on the payer side with respect to some of the the offshoring or setting up the manila facility I would say we're making very good progress. I would say some of the largest payers we've already worked through and have the consent to be able to process their claims offshore. Of course, anything with the US government, we're keeping all onshore and we're very careful about that from a compliance perspective and have the proper controls in place to make sure that we're monitoring that really on a case by case basis. But I've been pleased with the progress with the payers and we started with the largest payers and now we'll continue to work down the list to some smaller payers. I think To be completely transparent with you, there are some payers who prefer not to leverage the offshore capabilities. We respect that, and we can certainly accommodate that in our workflow and make sure that's the case. But the big payers are pretty well understanding of it. And frankly, in many cases, many of these big payers have offshoring capabilities of their very own set up in the same city centers that we're looking at setting up operations with. So we feel good about that and that we've made a lot of good progress around that effort.

Thank you. We have no further questions, so I'll now hand back over to the management team for closing remarks.

Terrific. Well, thank you. I will say we're extremely encouraged by the start of the year and the momentum that we see building within our business as we focus on driving towards our strategic objectives. I want to take the opportunity to thank all of our teams for their hard work, their dedication to really advancing our cause as we aim to serve all patients who can benefit from our products and services. That list continues to grow each and every day. Thank you for joining our call, and we look forward to catching up the next time.

This concludes today's call. Thank you for joining. You may now disconnect your line.